var data={"title":"Vinblastine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vinblastine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7151?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vinblastine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vinblastine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=vinblastine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vinblastine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708853\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">This preparation should be administered by individuals experienced in the administration of vinblastine sulfate. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Extravasation: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\"> It is extremely important that the intravenous needle or catheter be properly positioned before any vinblastine sulfate is injected. Leakage into surrounding tissue during intravenous administration of vinblastine may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate administration:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">For intravenous use only - fatal if given by other routes.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369039\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vinblastine Sulphate Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234144\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimicrotubular;</li>\n      <li>\n        Antineoplastic Agent, Vinca Alkaloid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234102\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Frequency and duration of therapy may vary by indication, concomitant combination chemotherapy and hematologic response. <b>For IV use only. </b>In order to prevent inadvertent intrathecal administration, the Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag (<b>NOT</b> a syringe).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hodgkin lymphoma, non-Hodgkin lymphomas (lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides), testicular cancer, Kaposi sarcoma, Langerhans cell histiocytosis (histiocytosis X, Letterer-Siwe disease):</b> <i>Manufacturer&rsquo;s labeling:</i> IV: 3.7 mg/m<sup>2</sup>; adjust dose every 7 days (based on white blood cell response) up to 5.5 mg/m<sup>2</sup> (second dose); 7.4 mg/m<sup>2</sup> (third dose); 9.25 mg/m<sup>2</sup> (fourth dose); and 11.1 mg/m<sup>2</sup> (fifth dose); do not administer more frequently than every 7 days. Usual dosage range: 5.5 to 7.4 mg/m<sup>2</sup> every 7 days; Maximum dose: 18.5 mg/m<sup>2</sup>; dosage adjustment goal is to reduce white blood cell count to ~3,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <span style=\"text-decoration: underline\">Off-label and/or indication-specific dosing:</span></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma (off-label dosing):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ABVD regimen: 6 mg/m<sup>2</sup> days 1 and 15 of a 28-day cycle (in combination with doxorubicin, bleomycin, dacarbazine, and radiation therapy) for 2 cycles (early/favorable disease) or for 4 cycles (early/unfavorable disease) (Eich 2010; Engert 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stanford V regimen: 6 mg/m<sup>2</sup> weeks 1, 3, 5, 7, 9, and 11 (in combination with doxorubicin, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) (Bartlett 1995; Gordon 2013; Horning 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Testicular cancer (off-label dosing):</b> VeIP regimen: IV: 0.11 mg/kg daily for 2 days every 21 days (in combination with ifosfamide, cisplatin, and mesna) for 4 cycles (Loehrer 1988; Loehrer 1988 [correction]; Loehrer 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bladder cancer (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Metastatic disease:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose-dense MVAC regimen: 3 mg/m<sup>2</sup> day 2 every 14 days (in combination with methotrexate, doxorubicin, cisplatin, and filgrastim) until disease progression or unacceptable toxicity (Sternberg 2001; Sternberg 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">MVAC regimen: 3 mg/m<sup>2</sup> days 2, 15, and 22 every 28 days (in combination with methotrexate, doxorubicin, and cisplatin) for up to 6 cycles (von der Maase 2000) <b>or</b> 3 mg/m<sup>2</sup> days 2, 15, and 22 every 28 days (in combination with methotrexate, doxorubicin, and cisplatin) until disease progression or unacceptable toxicity (Sternberg 2001; Sternberg 2006) <b>or</b> 3 mg/m<sup>2</sup> days 1, 15, and 22 every 28 days (in combination with methotrexate, doxorubicin, cisplatin, and filgrastim) for up to 6 cycles (Bamias 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neoadjuvant treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">MVAC regimen: 3 mg/m<sup>2</sup> days 2, 15, and 22 every 28 days (in combination with methotrexate, doxorubicin, and cisplatin) for 3 cycles (Grossman 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CMV regimen: 4 mg/m<sup>2</sup> days 1 and 8 every 21 days (in combination with methotrexate, cisplatin, and leucovorin) for 3 cycles (Griffiths 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma, metastatic (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVD regimen: 2 mg/m<sup>2</sup> days 1 to 4 and 22 to 25 of a 6-week treatment cycle (in combination with cisplatin and dacarbazine); may repeat if tumor response (Eton 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVD + immunotherapy regimen: 1.5 mg/m<sup>2</sup> days 1 to 4 and 22 to 25 of a 6-week treatment cycle (in combination with cisplatin, dacarbazine, aldesleukin, and interferon alfa-2b); may repeat if tumor response (Eton 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjuvant treatment after complete resection: 4 mg/m<sup>2</sup> days 1, 8, 15, 22, and 29, then every 2 weeks (in combination with cisplatin) until last cisplatin dose (Arriagada 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concurrent radiation: 5 mg/m<sup>2</sup> days 1, 8, 15, 22, and 29 (in combination with cisplatin and concurrent radiation therapy) (Curran 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Soft tissue sarcoma (desmoid tumors, aggressive fibromatosis), advanced (off-label use):</b> IV: 6 mg/m<sup>2</sup> every 7 to 10 days (dose usually rounded to 10 mg) in combination with methotrexate for 1 year (Azzarelli 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234123\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=vinblastine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vinblastine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Frequency and duration of therapy may vary by indication, concomitant combination chemotherapy and hematologic response. <b>For IV use only. </b>In order to prevent inadvertent intrathecal administration, the Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag (<b>NOT</b> a syringe).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma:</b> IV: Initial dose: 6 mg/m<sup>2</sup>; do not administer more frequently than every 7 days <b>or</b> ABVD regimen (off-label dosing; advanced disease): IV: 6 mg/m<sup>2</sup> days 1 and 15 of a 28-day cycle (in combination with doxorubicin, bleomycin, dacarbazine, and radiation therapy) for 6 cycles (Hutchinson 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Letterer-Siwe disease:</b> IV: Initial dose: 6.5 mg/m<sup>2</sup>; do not administer more frequently than every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Testicular cancer:</b> IV: Initial dose: 3 mg/m<sup>2</sup>; do not administer more frequently than every 7 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234103\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234104\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234105\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer&rsquo;s labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The following adjustments have also been recommended (Floyd 2006; Superfin 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum bilirubin &gt;3 times ULN: Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344289\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: </i> Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234079\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234064\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234082\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: <b>In order to prevent inadvertent intrathecal administration, the Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag (NOT in a syringe).</b> For IV administration only. <b>Fatal if given intrathecally.</b> The preferred administration is as a short infusion in a 25 to 50 mL minibag. If administration via a minibag is not possible, may also be administered as an undiluted 1-minute infusion into a free flowing IV line to prevent venous irritation/extravasation. Prolonged administration times (&ge;30 to 60 minutes) and/or increased administration volumes may increase the risk of vein irritation and extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (Perez Fidalgo 2012). Remaining portion of the vinblastine dose should be infused through a separate vein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> If needle/cannula still in place, administer 1 to 6 mL hyaluronidase (150 units/mL) into the existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (Perez Fidalgo 2012; Schulmeister 2011). If needle/cannula was removed, inject 1 to 6 mL (150 units/mL) subcutaneously in a clockwise manner using 1 mL for each 1 mL of drug extravasated (Schulmeister 2011) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (using a 25-gauge needle) subcutaneously into the extravasation site (Polovich 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132729\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234080\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin Lymphoma:</b> Treatment of Hodgkin lymphoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Kaposi sarcoma:</b> Treatment of Kaposi sarcoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Langerhans cell histiocytosis: </b>Treatment of histiocytosis X (Letterer-Siwe disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphomas:</b> Treatment of lymphocytic lymphoma, histiocytic lymphoma, and mycosis fungoides</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Testicular cancer:</b> Treatment of testicular cancer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used in the treatment of refractory or resistant breast cancer and resistant choriocarcinoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744939\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bladder cancer; Melanoma (metastatic); Non-small cell lung cancer (NSCLC); Soft tissue sarcoma (desmoid tumors, aggressive fibromatosis), advanced</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234153\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">VinBLAStine may be confused with vinCRIStine, vinorelbine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">For IV use only. Fatal if administered by other routes. To prevent fatal inadvertent intrathecal injection, it is strongly recommended that vinblastine doses be dispensed in a small minibag (25 to 50 mL of a compatible solution), and <b>NOT</b> a syringe (ISMP 2014). Vinblastine should <b>NOT </b>be prepared during the preparation of any intrathecal medications. After preparation, keep vinblastine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Vinblastine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234071\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cerebrovascular accident, ECG abnormality, hypertension (common), ischemic heart disease, limb ischemia, myocardial infarction, Raynaud's phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Decreased deep tendon reflex, depression, dizziness, headache, malaise (common), metallic taste, neurotoxicity (duration: &gt;24 hours), paresthesia, peripheral neuritis, seizure, tumor pain (common), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia (common), dermatitis, skin blister, skin photosensitivity (rare), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperuricemia, SIADH (syndrome of inappropriate antidiuretic hormone secretion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation (common), diarrhea, enterocolitis (hemorrhagic), gastrointestinal hemorrhage, intestinal obstruction, nausea (mild), paralytic ileus, stomatitis, toxic megacolon, vomiting (mild)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Azoospermia, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bone marrow depression (common), granulocytopenia (common; nadir: 5 to 10 days; recovery: 7 to 14 days; dose-limiting toxicity), hemolytic uremic syndrome, leukopenia (common; nadir: 5 to 10 days; recovery: 7 to 14 days; dose-limiting toxicity), rectal hemorrhage, thrombocytopenia (recovery within a few days), thrombotic thrombocytopenic purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Jaw pain (common), myalgia, ostealgia (common), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory disturbance, deafness, vestibular disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea, pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Radiation recall phenomenon</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234085\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Significant granulocytopenia (unless as a result of condition being treated); presence of bacterial infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications not in the US labeling: Pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234068\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Leukopenia commonly occurs; granulocytopenia may be severe with higher doses. The leukocyte nadir generally occurs 5 to 10 days after administration; recovery typically occurs 7 to 14 days later. Monitor for infections if WBC &lt;2,000/mm<sup>3</sup>. Leukopenia may be more pronounced in cachectic patients and patients with skin ulceration and may be less pronounced with lower doses used for maintenance therapy. Leukocytes and platelets may fall considerably with moderate doses when marrow is infiltrated with malignant cells (further use in this situation is not recommended). Thrombocytopenia and anemia may occur rarely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: <b>[US Boxed Warning]: Vinblastine is a vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. Extravasation may cause significant irritation. Individuals administering should be experienced in vinblastine administration. If extravasation occurs, discontinue immediately and initiate appropriate extravasation management, including local injection of hyaluronidase and moderate heat application to the affected area. Use a separate vein to complete administration.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Stomatitis may occur (rare); may be disabling, but is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: May rarely cause disabling neurotoxicity; usually reversible. Seizures and severe and permanent CNS damage has occurred with higher then recommended doses and/or when administered more frequently than recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Acute shortness of breath and severe bronchospasm have been reported, most often in association with concurrent administration of mitomycin; may occur within minutes to several hours following vinblastine administration or up to 14 days following mitomycin administration; use caution in patients with preexisting pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; toxicity may be increased; may require dosage modification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic heart disease: Use with caution in patients with ischemic heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hazardous agent: Avoid eye contamination (exposure may cause severe irritation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; NOT for intrathecal use: <b>[US Boxed Warning]: For IV use only. </b><b>Intrathecal administration may result in death.</b> To prevent administration errors, the Institute for Safe Medication Practices (ISMP) Targeted Medication Safety Best Practices for Hospitals initiative strongly recommends dispensing vinblastine diluted in a minibag (ISMP 2014). <b> If not dispensed in a minibag, affix an auxiliary label stating &quot;For intravenous use only - fatal if given by other routes&quot; and also place in an overwrap labeled &quot;Do not remove covering until moment of injection.&quot;</b> Vinblastine should <b>NOT </b>be prepared during the preparation of any intrathecal medications. After preparation, keep vinblastine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Vinblastine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234139\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234073\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10044&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of VinBLAStine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May increase the serum concentration of VinBLAStine. Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Avoid the concomitant use of posaconazole and vinca alkaloids when possible. If combined, monitor for increased vinca alkaloid toxicities (eg, neurotoxicity, gastrointestinal toxicity).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of VinBLAStine. Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolterodine: VinBLAStine may increase the serum concentration of Tolterodine.  Management: Reduce tolterodine dose to 1 mg twice daily (regular release formulation) or 2 mg daily (extended release formulation) (adult doses) and monitor for increased levels/effects of tolterodine with initiation of vinblastine therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234075\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6753821\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy.  Women of childbearing potential should avoid becoming pregnant during vinblastine treatment. Aspermia has been reported in males who have received treatment with vinblastine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6753863\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if vinblastine is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made whether to discontinue vinblastine or to discontinue breastfeeding, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234077\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, serum uric acid, hepatic function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234067\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vinblastine binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vinblastine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234084\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (via CYP3A) to active metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: ~25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (10%); urine (14%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324092\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (VinBLAStine Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (10 mL): $51.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234088\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Blastovin (PY);</li>\n      <li>Blastovin PF (IL);</li>\n      <li>Blestinib (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cytoblastin (BG, IN, VN);</li>\n      <li>Lemblastine (CL, CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Oncoblastin (CO, PE);</li>\n      <li>Oncostin (PH);</li>\n      <li>Velbastine (HK, KR, PH, SG);</li>\n      <li>Velbe (AE, AR, AT, AU, BE, BF, BH, BJ, CH, CI, CZ, DE, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, HR, IE, IT, KE, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, PK, PL, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, TN, TR, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Vilban (LK);</li>\n      <li>Vinatin (BR);</li>\n      <li>Vinblastin (HU, PL);</li>\n      <li>Vinblastina (CO);</li>\n      <li>Vinblastine Sulfate Injection (AU);</li>\n      <li>Xintoprost (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14736927\"></a>Arriagada R, Bergman B, Dunant A, et al, &ldquo;Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non-Small-Cell Lung Cancer,&rdquo; <i>N Engl J Med</i>, 2004, 350(4):351-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/14736927/pubmed\" target=\"_blank\" id=\"14736927\">14736927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11571741\"></a>Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.. <i>Cancer</i>. 2001;92(5):1259-1264.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/11571741/pubmed\" target=\"_blank\" id=\"11571741\">11571741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14665607\"></a>Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group [published correction appears in <i>J Clin Oncol</i>. 2004;22(9):1771]. <i>J Clin Oncol</i>. 2004;22(2):220-228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/14665607/pubmed\" target=\"_blank\" id=\"14665607\">14665607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartlett NL, Rosenberg SA, Hoppe RT, et al, &ldquo;Brief Chemotherapy, Stanford V, and Adjuvant Radiotherapy for Bulky or Advanced-Stage Hodgkin&rsquo;s Disease: A Preliminary Report,&rdquo; <i>J Clin Oncol</i>, 1995, 13(5):1080-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/ 7537796/pubmed\" target=\"_blank\" id=\" 7537796\"> 7537796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bashir H, Motl S, Metzger ML, et al, &ldquo;Itraconazole-Enhanced Chemotherapy Toxicity in a Patient With Hodgkin Lymphoma,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2006, 28(1):33-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/16394890/pubmed\" target=\"_blank\" id=\"16394890\">16394890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2709240\"></a>Beijnen JH, Vendrig DE, Underberg WJ. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. <i>J Parenter Sci Technol</i>. 1989;43(2):84-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/2709240/pubmed\" target=\"_blank\" id=\"2709240\">2709240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonadonna G, Valagussa P, and Santoro A, &ldquo;Alternating Non-Cross-Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin's Disease: A Report of 8-Year Results,&rdquo; <i>Ann Intern Med</i>, 1986, 104(6):739-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/2422994/pubmed\" target=\"_blank\" id=\"2422994\">2422994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21903745\"></a>Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. <i>J Natl Cancer Inst</i>. 2011;103(19):1452-1460.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/21903745/pubmed\" target=\"_blank\" id=\"21903745\">21903745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eich HT, Diehl V, G&ouml;rgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. <i>J Clin Oncol</i>. 2010;28(27):4199-4206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/20713848/pubmed\" target=\"_blank\" id=\"20713848\">20713848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engert A, Franklin J, Eich HT, et al, &ldquo;Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin&rsquo;s Lymphoma: Final Results of the GHSG HD7 Trial,&rdquo; <i>J Clin Oncol</i>, 2007, 25(23):3495-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/17606976/pubmed\" target=\"_blank\" id=\"17606976\">17606976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11956264\"></a>Eton O, Legha SS, Bedikian AY, et al, &ldquo;Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial,&rdquo; <i>J Clin Oncol</i>, 2002, 20(8):2045-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/11956264/pubmed\" target=\"_blank\" id=\"11956264\">11956264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &quot;Hepatotoxicity of Chemotherapy,&quot; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo; <i>J Clin Oncol</i>, 2005, 23(30):7685-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/16234530/pubmed\" target=\"_blank\" id=\"16234530\">16234530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23182987\"></a>Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>J Clin Oncol</i>. 2013;31(6):684-691. doi: 10.1200/JCO.2012.43.4803.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/23182987/pubmed\" target=\"_blank\" id=\"23182987\">23182987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21502557\"></a>Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. <i>J Clin Oncol</i>. 2011;29(16):2171-2177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/21502557/pubmed\" target=\"_blank\" id=\"21502557\">21502557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12944571\"></a>Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced Bladder Cancer. <i>N Engl J Med</i>. 2003;349(9):859-866.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/12944571/pubmed\" target=\"_blank\" id=\"12944571\">12944571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horning SJ, Hoppe RT, Breslin S, et al, &ldquo;Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,&rdquo; <i>J Clin Oncol</i>, 2002, 20(3):630-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/11821442/pubmed\" target=\"_blank\" id=\"11821442\">11821442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. <i>J Clin Oncol</i>. 1998;16(3):897-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/9508171/pubmed\" target=\"_blank\" id=\"9508171\">9508171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices. 2014-2015 Targeted Medication Safety Best Practices for Hospitals. Available at http://www.ismp.org/tools/bestpractices/TMSBP-for-Hospitals.pdf. Accessed September 26, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loehrer PJ Sr, Gonin R, Nichols CR, et al, &ldquo;Vinblastine Plus Ifosfamide Plus Cisplatin as Initial Salvage Therapy in Recurrent Germ Cell Tumor,&rdquo; <i>J Clin Oncol</i>, 1998, 16(7):2500-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/9667270/pubmed\" target=\"_blank\" id=\"9667270\">9667270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. <i>Ann Intern Med</i>. 1988;109(7):540-546.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/2844110/pubmed\" target=\"_blank\" id=\"2844110\">2844110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loehrer PJ Sr. Correction: Incomplete Dosage Information in Article on Germ Cell Cancer. <i>Ann Intern Med</i>. 1988;109(10):846.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):vii167-vii173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polovich M, Whitford JN, Olsen M. <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed. Pittsburgh, PA: Oncology Nursing Society; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schulmeister L. Extravasation management: clinical update. <i>Semin Oncol Nurs</i>. 2011;27(1):82-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/21255716/pubmed\" target=\"_blank\" id=\"21255716\">21255716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11352955\"></a>Sternberg CN, de Mulder PH, Schornagel JH, et al, &ldquo;Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic M-VAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924,&rdquo; <i>J Clin Oncol</i>, 2001, 19(10):2638-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/11352955/pubmed\" target=\"_blank\" id=\"11352955\">11352955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16330205\"></a>Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. <i>Eur J Cancer</i>. 2006;42(1):50-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/16330205/pubmed\" target=\"_blank\" id=\"16330205\">16330205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Superfin D, Iannucci AA, and Davies AM, &ldquo;Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary,&rdquo; <i>Oncologist</i>, 2007, 12(9):1070-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/17914077/pubmed\" target=\"_blank\" id=\"17914077\">17914077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11001674\"></a>von der Maase H, Hansen SW, Roberts JT, et al, &ldquo;Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study,&rdquo; <i>J Clin Oncol</i>, 2000, 18(17):3068-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-drug-information/abstract-text/11001674/pubmed\" target=\"_blank\" id=\"11001674\">11001674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vinblastine (prescribing information). Schaumburg, IL: APP Pharmaceuticals, LLC; October, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vinblastine Sulfate Injection (product monograph). Kirkland, Quebec, Canada: Pfizer Canada Inc; August 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10044 Version 173.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708853\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16369039\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F234144\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F234102\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F234123\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F234103\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F234104\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F234105\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344289\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F234079\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F234064\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F234082\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132729\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F234080\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744939\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F234153\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234071\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F234085\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F234068\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F234139\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F234073\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F234075\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6753821\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6753863\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F234077\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F234067\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F234084\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324092\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F234088\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10044|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vinblastine-patient-drug-information\" class=\"drug drug_patient\">Vinblastine: Patient drug information</a></li><li><a href=\"topic.htm?path=vinblastine-pediatric-drug-information\" class=\"drug drug_pediatric\">Vinblastine: Pediatric drug information</a></li></ul></div></div>","javascript":null}